Oligo-Metastatic Cancers: Putative Biomarkers, Emerging Challenges and New Perspectives

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Oligometastatic disease (OMD) is a clinical presentation of cancer metastasis characterized by limited tumor burden and fewer metastatic sites.
• OMD may represent a distinct biological entity separate from widespread metastatic disease.
• Understanding OMD is crucial for refining cancer staging and treatment strategies.

Purpose of the Study:

• To review emerging biomarkers associated with oligometastatic disease (OMD).
• To discuss methodological challenges in studying OMD, particularly in clinical trials.
• To explore future perspectives for characterizing and treating OMD.

Main Methods:

• Literature review of recent studies on OMD.
• Analysis of identified biomarkers including microRNA profiles, genetic mutations, and immune cell infiltration.
• Discussion of clinical trial design and staging system considerations for OMD.

Main Results:

• Specific microRNA profiles, chromosome patterns, and driver gene mutations (e.g., ERBB2, KRAS, PIK3CA) are linked to OMD.
• Immune cell infiltration levels correlate with oligometastatic behavior.
• Polymorphisms like TCF7L2 may also be associated with OMD.

Conclusions:

• OMD exhibits unique molecular and biological characteristics, suggesting it is a distinct disease entity.
• Methodological challenges in clinical trials due to tumor burden heterogeneity need addressing.
• Further understanding of OMD's features will improve clinical staging and enable personalized treatment approaches.